A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom

Name: A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom
Published: 2020
License: Public Domain

Bristol-Myers Squibb · 2020

ClinicalTrials.gov · Datasets · License: Public Domain · 2020

Open Source ↗

esophageal-squamous-cell-carcinoma nivolumab quality-of-life real-world-evidence survival

esophageal squamous cell carcinoma, bms-936558, early access to medicines scheme, eams, nivolumab, prospective study, quality of life, real world evidence, squamous cell oesophageal carcinoma, survival, observational

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom

Related documents